Omics Technology facility

组学技术设施

• 批准号: 10703083
• 负责人: Liang Cao
• 金额: $ 82.28万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10703083
• 关键词: ATAC-seq; Algorithms; Antibodies; Area; Bioinformatics; Biological; Biological Assay; Biology; CCR; Cells; ChIP-seq; Classification; Clinical; Communities; Computational Biology; Contractor; Cooperative Research and Development Agreement; Custom; DNA; DNA analysis; DNA sequencing; Data; Data Analyses; Detection; Development; Enhancers; Epigenetic Process; Foundations; Funding; Gene Rearrangement; Genes; Genetic; Genome; Goals; Immunogenomics; Industrialization; Intention; Internet; Laboratories; Left; Machine Learning; Malignant Neoplasms; Mediating; Methods; Micrococcal Nuclease; Molecular Profiling; Molecular Target; Mutation Detection; Oncogenes; Positioning Attribute; Proteomics; Protocols documentation; RNA; Research; Research Personnel; Resources; Sequence Analysis; Structure; T-Lymphocyte; Technology; Training; Tumor Antigens; United States National Institutes of Health; Validation; Work; assay development; base; biomarker development; clinical biomarkers; convolutional neural network; epigenetic regulation; exome sequencing; genome sequencing; innovation; mass spectrometric imaging; member; new technology; next generation sequencing; operation; recruit; response; screening; single-cell RNA sequencing; targeted sequencing; technology development; tool; transcriptome sequencing; tumor; whole genome

As the project was started in this fiscal year, the main effort was focused on the establishment of operation and in the development of core technologies. A. Team formation: 1. Web lab: Two additional members were transferred to us in April of FY22 from the previous Molecular Profile/Clinomics Core, one of which had since left NCI in June 22. We'll fill in this vacate position in FY23. 2. IT team: Two members were recruited to the IT team via the NCI Frederick contractor. This IT team is currently helping to establish the pipelines for Next Generation Sequencing (NGS) data analysis. B. Core technology development. We are mainly focused on establishing NGS-based technologies for discovery cancer drivers, and for understanding biological mechanisms. Specifically, the following technologies are established or near establishment. 1. NGS for cancer mutation detection. We adapted methods for both DNA and RNA Exome sequencing aimed for detection SNV, deletion, an insertion. 2. NGS for expression and fusion detection. The staff in the lab were trained for RNA Exome seq for the detection of fusions, and for expression analysis. 3. Epigenetic regulation. We adapted two different methods for chip-seq, including antibody-mediated DNA cutting by micrococcal nucleases and transposes. 4. Targeted sequencing of cancer gene panels 5. Customized assay development and sequencing of genes involved in T-cell mediated responses against tumor antigens 6. Validation of the NGS methods for their intended research or clinical use, respectively 7. Refining the analytical pipelines for NGS data analysis

由于该项目在本财政年度启动，主要工作集中在 建立业务和开发核心技术。A.团队组建：1. Web实验室：2022财年4月，又有两名成员从之前的 分子概况/临床组学核心，其中一个自6月22日离开NCI。我们会填补 这一职位将在2023财年空缺。2. IT团队：两名成员通过 弗雷德里克承包商。该IT团队目前正在帮助建立管道， 下一代测序（NGS）数据分析。B。核心技术开发。我们主要 专注于建立基于NGS的技术，用于发现癌症驱动因素， 了解生物机制。具体而言，建立了以下技术 或接近建立。1.用于癌症突变检测的NGS。我们采用了两种DNA 以及RNA外显子组测序，旨在检测SNV、缺失、插入。2. NGS用于 表达和融合检测。实验室的工作人员接受了RNA外显子组测序的培训， 融合检测和表达分析。3.表观遗传调节。我们改编了两个 不同的芯片测序方法，包括抗体介导的微球菌DNA切割， 核酸酶和转座。4.癌症基因组的靶向测序5.定制检测 参与T细胞介导的抗肿瘤反应的基因的开发和测序 抗原6.验证NGS方法用于其预期研究或临床用途， 分别为7。优化NGS数据分析的分析管道